{"id":"omega-3-atorvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Fish-like aftertaste"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination drug leverages omega-3 polyunsaturated fatty acids (EPA/DHA) to decrease plasma triglycerides and reduce vascular inflammation, while atorvastatin blocks cholesterol synthesis by inhibiting the rate-limiting enzyme HMG-CoA reductase. Together, they provide complementary lipid-lowering and cardioprotective effects for cardiovascular risk reduction.","oneSentence":"Omega-3 fatty acids reduce triglycerides and inflammation while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:16.786Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia and hypertriglyceridemia"},{"name":"Cardiovascular disease prevention"}]},"trialDetails":[{"nctId":"NCT05365438","phase":"PHASE4","title":"Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2022-10-01","conditions":"Dyslipidemias, Atherosclerosis, Diabetes Mellitus, Type 2","enrollment":105},{"nctId":"NCT03510884","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-05-31","conditions":"Hypercholesterolaemia","enrollment":153},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT00141232","phase":"PHASE4","title":"Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Diabetes, Type 2","enrollment":810},{"nctId":"NCT03510715","phase":"PHASE3","title":"An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-31","conditions":"Hypercholesterolemia","enrollment":18},{"nctId":"NCT00072826","phase":"PHASE1","title":"Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2003-11-04","conditions":"Sickle Cell Disease","enrollment":44},{"nctId":"NCT02942602","phase":"NA","title":"Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2014-04-03","conditions":"Hyperlipidemia","enrollment":58},{"nctId":"NCT03438955","phase":"PHASE1","title":"Phase I Drug-drug Interaction of Omega-3 and Atorvastatin","status":"UNKNOWN","sponsor":"DongKoo Bio & Pharma","startDate":"2018-02-01","conditions":"Hyperlipidemia, Hypertriglyceridemia","enrollment":48},{"nctId":"NCT00435045","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Hypertriglyceridemia","enrollment":245},{"nctId":"NCT02305355","phase":"PHASE4","title":"Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2, Hypertriglycemia","enrollment":68},{"nctId":"NCT02035215","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia","status":"UNKNOWN","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2014-01","conditions":"Hyperlipidemia, Familial Combined","enrollment":80},{"nctId":"NCT01259284","phase":"PHASE2, PHASE3","title":"Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01","conditions":"Advanced Cancers","enrollment":2},{"nctId":"NCT00760786","phase":"NA","title":"Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2008-07","conditions":"Acute Coronary Syndrome","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Atmeg-Omethyl cutielet","Atmeg"],"phase":"marketed","status":"active","brandName":"Omega 3-Atorvastatin","genericName":"Omega 3-Atorvastatin","companyName":"Seoul National University Bundang Hospital","companyId":"seoul-national-university-bundang-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Omega-3 fatty acids reduce triglycerides and inflammation while atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol. Used for Hyperlipidemia and hypertriglyceridemia, Cardiovascular disease prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}